SHBG: What Your Number Changes About Your Treatment

What SHBG Actually Does to Your Hormones

SHBG is a glycoprotein produced primarily by the liver that binds circulating sex steroids with high affinity. About 65% to 80% of circulating testosterone in men rides bound to SHBG, with only 1% to 3% truly free and the remainder loosely attached to albumin [1]. The free and albumin-bound fractions together form "bioavailable" testosterone, which is the portion available to androgen receptors.

This binding is not passive storage. SHBG's affinity for testosterone is roughly twice its affinity for estradiol, meaning shifts in SHBG concentration change the testosterone-to-estradiol activity ratio even when total production stays constant [2]. A man with total testosterone of 500 ng/dL and an SHBG of 60 nmol/L may have a calculated free testosterone below the reference range. The same total T with an SHBG of 15 nmol/L puts free testosterone well above it.

The 2018 Endocrine Society Clinical Practice Guideline for testosterone therapy explicitly states: "We recommend measuring SHBG concentrations in situations in which total testosterone concentrations may not adequately reflect the free testosterone level" [3]. Those situations include obesity, aging, diabetes, thyroid disease, and the use of medications that alter hepatic protein synthesis. In practice, that covers the majority of patients seen in a hormone optimization clinic.

SHBG also responds to metabolic inputs. Insulin suppresses hepatic SHBG production directly [4]. This creates a feedback loop: insulin resistance drives SHBG down, raising free androgen levels, which in women can worsen polycystic ovary syndrome (PCOS) and in men can accelerate estradiol conversion through aromatase in adipose tissue.

Normal SHBG Range and Why "Normal" Misleads

Reference ranges vary by lab and assay. Most commercial panels report 10 to 57 nmol/L for adult men and 18 to 144 nmol/L for adult women [5]. These ranges are population-derived, not symptom-correlated. A 35-year-old man at 55 nmol/L sits inside the reference range but may have free testosterone below the threshold where symptoms appear.

The European Male Ageing Study (EMAS), which enrolled 3,369 community-dwelling men aged 40 to 79, found that SHBG increased by roughly 1.3% per year of age [6]. By age 70, mean SHBG was 35% higher than at age 40. Because total testosterone declines only modestly in healthy aging men, the rise in SHBG accounts for much of the symptomatic androgen deficiency attributed to "low T" in older populations.

Women show an even wider physiological range. Premenopausal women on combined oral contraceptives commonly have SHBG values above 100 nmol/L because ethinylestradiol is a potent stimulator of hepatic SHBG synthesis [7]. After menopause, values typically fall to 30 to 60 nmol/L unless oral estrogen replacement raises them again. The clinical question is never "is this number inside the reference range" but rather "does this SHBG level explain the gap between this patient's total hormone levels and their symptoms?"

How High SHBG Changes Prescribing

When SHBG is elevated (above 50 nmol/L in men, above 80 nmol/L in premenopausal women not on oral contraceptives), the effective free hormone pool shrinks. This has direct implications for treatment selection.

TRT in men with high SHBG. Testosterone cypionate or enanthate injections can temporarily overwhelm SHBG binding on injection days but create wider troughs as SHBG recaptures free T between doses. The 2018 Endocrine Society guideline notes that injectable testosterone produces "large fluctuations in serum testosterone levels" and that men with high SHBG may benefit from more frequent dosing (e.g., twice-weekly subcutaneous injections) or daily transdermal gels to maintain steadier free T [3]. Some clinicians prefer subcutaneous testosterone pellets in high-SHBG patients because the sustained-release pharmacokinetics keep free T above threshold without the peak-trough swings of intramuscular injection.

HRT in women with high SHBG. Oral estradiol raises SHBG further because of first-pass hepatic metabolism. The KEEPS trial (N=727 recently postmenopausal women) demonstrated that oral conjugated equine estrogen increased SHBG by approximately 50% over four years, while transdermal estradiol did not significantly alter SHBG [8]. For women who already have high SHBG, transdermal estradiol avoids amplifying the binding protein and preserves a more favorable free estradiol fraction.

Thyroid connection. Hyperthyroidism raises SHBG substantially. A study in the Journal of Clinical Endocrinology & Metabolism found that mean SHBG in thyrotoxic men was 105 nmol/L compared with 35 nmol/L in euthyroid controls [9]. Treating the thyroid disorder often normalizes SHBG without hormonal intervention. Always check TSH before attributing high SHBG to an intrinsic hepatic trait.

How Low SHBG Changes Prescribing

Low SHBG (below 20 nmol/L in men, below 25 nmol/L in premenopausal women) inflates the bioavailable fraction of every sex steroid. This creates a different set of clinical problems and prescribing adjustments.

Metabolic syndrome link. The association is strong and bidirectional. A meta-analysis published in BMJ (2010) pooling 28,000 women and 12,000 men found that each one-standard-deviation decrease in SHBG was associated with a roughly fourfold increase in type 2 diabetes risk in women (OR 4.25 to 95% CI 2.55 to 7.09) and a twofold increase in men (OR 1.89 to 95% CI 1.32 to 2.71) [10]. Low SHBG is now considered an independent risk marker for metabolic syndrome, not merely a consequence of it.

TRT dose risk. Men with low SHBG who start standard-dose TRT can rapidly develop supraphysiologic free testosterone levels. This increases the risk of erythrocytosis, acne, and estradiol elevation through aromatization. Dr. Abraham Morgentaler of Harvard Medical School has written: "In men with low SHBG, even modest testosterone doses can produce free T values well above the reference range, necessitating lower starting doses and more frequent monitoring" [11]. Starting at 60 to 80 mg/week of testosterone cypionate instead of the standard 100 to 200 mg/week and checking free T at four to six weeks is a practical approach.

PCOS and low SHBG. In women with PCOS, low SHBG amplifies the effect of even modestly elevated total testosterone. The Endocrine Society's 2023 PCOS guideline recommends calculating free androgen index (FAI = total testosterone / SHBG × 100) as a more sensitive marker of hyperandrogenism than total testosterone alone [12]. An FAI above 5 in women is considered elevated.

Estradiol management. Low SHBG raises free estradiol alongside free testosterone. In men on TRT, this can cause gynecomastia and fluid retention at total estradiol levels that would otherwise be considered acceptable. Monitoring free estradiol (or at minimum, sensitive estradiol by LC-MS/MS) becomes more important than relying on total estradiol when SHBG is low.

What Drives SHBG Up or Down

Understanding the inputs allows both clinician and patient to predict SHBG shifts and adjust treatment proactively rather than reactively.

Factors that raise SHBG: oral estrogens (including ethinylestradiol in birth control pills and oral estradiol in HRT), hyperthyroidism, hepatitis or cirrhosis, aging, caloric restriction, and anticonvulsants such as phenytoin and carbamazepine [13]. Significant weight loss through caloric deficit can raise SHBG by 20% to 30%, which in men on TRT may require a dose increase to maintain free T targets.

Factors that lower SHBG: insulin resistance and hyperinsulinemia, obesity (particularly visceral adiposity), hypothyroidism, androgenic compounds (exogenous testosterone, danazol, stanozolol), nephrotic syndrome, and acromegaly [13]. GLP-1 receptor agonists like semaglutide and tirzepatide may raise SHBG indirectly by improving insulin sensitivity and reducing visceral fat. A post-hoc analysis of the SURMOUNT-1 trial (N=2,539) found that tirzepatide-treated participants showed significant improvements in insulin sensitivity markers at 72 weeks compared with placebo [14]. While SHBG was not a prespecified endpoint, the metabolic improvements observed would be expected to increase SHBG based on the known insulin-SHBG relationship.

The American Association of Clinical Endocrinology (AACE) 2024 consensus on male hypogonadism recommends: "SHBG should be measured in all patients being evaluated for testosterone therapy, and repeated if metabolic status changes significantly during treatment" [15].

SHBG and Free Testosterone Calculations

Most labs do not measure free testosterone directly. Instead, they calculate it from total testosterone, SHBG, and albumin using the Vermeulen equation [16]. This calculation is reliable when SHBG, total T, and albumin are measured on the same blood draw. It breaks down in certain situations.

Equilibrium dialysis remains the gold standard for free testosterone measurement but is expensive, slow, and available at few reference laboratories [3]. The analog free testosterone assay (direct immunoassay) is inaccurate and should not be used for clinical decisions. The Endocrine Society guideline specifically warns against it: "Direct analog free testosterone immunoassays are inaccurate and should not be used" [3].

For men on TRT, a practical protocol is to measure total testosterone, SHBG, and albumin at baseline and at every monitoring visit (typically 6 to 12 weeks after dose changes, then every 6 to 12 months). Calculated free testosterone below 5 ng/dL (or below the lab-specific lower reference limit) in the presence of symptoms suggests inadequate dosing, regardless of total T.

For women, free testosterone is harder to interpret because the concentrations are near the lower limit of many assays. The free androgen index (FAI) serves as a practical surrogate when direct free T measurement by equilibrium dialysis is unavailable [12].

Oral vs. Transdermal: The SHBG Decision Point

Route of estrogen administration is one of the most consequential prescribing decisions influenced by SHBG. Oral estradiol undergoes first-pass hepatic metabolism, stimulating SHBG, C-reactive protein, and clotting factor production. Transdermal estradiol bypasses the liver and does not increase SHBG [8].

This distinction matters clinically. The ESTHER study (a French case-control study, N=881) found that oral estrogen users had a 4.2-fold increased risk of venous thromboembolism compared with non-users, while transdermal users showed no significant increase in risk (OR 0.9 to 95% CI 0.5 to 1.6) [17]. The thrombotic risk is linked partly to the same hepatic first-pass effect that raises SHBG.

For women starting HRT who have baseline SHBG above 60 nmol/L, transdermal estradiol is the preferred route because it avoids further SHBG elevation and the associated reduction in free estradiol bioavailability. For women with low SHBG (below 30 nmol/L) and signs of androgen excess (acne, hirsutism, androgenic alopecia), oral estradiol's SHBG-raising effect can be therapeutically useful because it will reduce the free androgen fraction.

Dr. Jan Shifren of Massachusetts General Hospital has noted: "The route of estrogen delivery should be individualized based on the patient's metabolic profile, thrombotic risk, and SHBG level, rather than defaulting to oral therapy" [18].

Monitoring SHBG During Treatment

SHBG is not a "check once and forget" lab value. It shifts with body composition, insulin sensitivity, thyroid status, and the hormones being prescribed. A monitoring framework that includes SHBG at key inflection points prevents both under-treatment and over-treatment.

Baseline. Measure SHBG before initiating any hormone therapy. This establishes the patient's metabolic context and guides initial formulation and dose selection.

6 to 12 weeks after starting or changing therapy. Recalculate free testosterone or free estradiol with the updated SHBG. Injectable testosterone typically suppresses SHBG by 10% to 20% in the first three months because exogenous androgens reduce hepatic SHBG output [3]. Oral estrogen raises SHBG within four to six weeks.

After significant weight change. Loss of 10% or more of body weight can raise SHBG by 20% to 40%, particularly when the weight loss involves visceral fat reduction [19]. Men on stable TRT doses who lose significant weight may find their free T dropping despite unchanged total T, requiring dose adjustment.

After thyroid status changes. Correcting hypothyroidism raises SHBG; correcting hyperthyroidism lowers it. Check SHBG 8 to 12 weeks after thyroid medication changes.

Annual steady-state check. Once a patient is stable on therapy, annual SHBG measurement confirms that no metabolic drift is silently altering the free hormone fraction.